Trevena’s (NASDAQ:TRVN) pain drug oliceridine is expecting an FDA decision coming November 2. Furthermore, the FDA has informed the company that it intends to …
Analysts chime in across the Street on potential approval odds for TRVN’s pain management drug oliceridine and ARRY’s cancer combination therapy of encorafenib with binimetinib.
Analysts are cautious to sure-fire confident on mover and shakers sending the Street into a frenzy today.
Trevena Inc (NASDAQ:TRVN) shares are tumbling nearly 16% to $1.98 in after-hours trading Wednesday, after the biopharmaceutical company announced that the development of …
